Literature DB >> 16996843

Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study.

Alexander Staudt1, Astrid Hummel, Jörg Ruppert, Marcus Dörr, Christiane Trimpert, Katrin Birkenmeier, Thomas Krieg, Yvonne Staudt, Stephan B Felix.   

Abstract

BACKGROUND: Various randomized studies evidenced that immunoadsorption (IA) repeated at monthly intervals induced acute and prolonged hemodynamic benefit in patients with severe heart failure due to dilated cardiomyopathy. Some findings indicate that the use of only one course of IA therapy may also induce prolonged beneficial effects.
METHODS: This randomized study included 22 patients suffering from severe heart failure (left ventricular ejection fraction [LVEF] <35%) due to dilated cardiomyopathy. The first group (11 patients) was treated with four IA courses at monthly intervals. The second group (11 patients) received one IA course only without repetition. In all patients of the 2 groups, each course was performed in one IA session on 5 consecutive days. At 3 and 6 months after the beginning of this study, left ventricular function and hemodynamics were reevaluated in both groups.
RESULTS: Immunoadsorption treatment repeated at monthly intervals induced improvement in LVEF after 6 months, that is, from 28.1% +/- 1.5% to 37.0% +/- 1.6% (+/-SEM; P < .01 vs baseline). Patients treated in only one IA course experienced comparable improvement of LVEF after 6 months, that is, from 26.5% +/- 2.2% to 34.8% +/- 2.9% (P < .01 vs baseline). In the group with repeated IA courses, cardiac index increased from baseline 2.2 +/- 0.1 to 2.8 +/- 0.2 L min(-1) m(-2) after 6 months (P < .01 vs baseline). In comparison, during the 6 months of this study in the group with one IA course, cardiac index increased from 2.1 +/- 0.1 to 2.7 +/- 0.2 L min(-1) m(-2). After 3 and 6 months, there were no significant differences between the 2 groups with respect to LVEF and all measured hemodynamic parameters.
CONCLUSIONS: One course of IA treatment may induce improvement of left ventricular function over a period of 6 months, with results comparable to those received by IA treatment repeated at monthly intervals.

Entities:  

Mesh:

Year:  2006        PMID: 16996843     DOI: 10.1016/j.ahj.2006.06.027

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  26 in total

Review 1.  Immune modulation in heart failure: past challenges and future hopes.

Authors:  Jose H Flores-Arredondo; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Curr Heart Fail Rep       Date:  2011-03

Review 2.  Autoantibodies and cardiovascular dysfunction: cause or consequence?

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-12

3.  Safety and Efficacy of Immunoadsorption as an Add-On to Medical Treatment in Patients with Severe Idiopathic Pulmonary Arterial Hypertension.

Authors:  Christian Nagel; Ralf Ewert; Benjamin Egenlauf; Hans B Lehmkuhl; Stephan Rosenkranz; Nicola Benjamin; Vedat Schwenger; Felix J F Herth; Ekkehard Grünig
Journal:  Respiration       Date:  2017-08-05       Impact factor: 3.580

4.  Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults--towards identification of myocardial inflammation.

Authors:  Antje Voigt; Thomas Elgeti; Tahir Durmus; Merve Ece Idiz; Craig Butler; Mark Beling; Rene Schilling; Karin Klingel; Reinhard Kandolf; Karl Stangl; Matthias Taupitz; Dietmar Kivelitz; Moritz Wagner
Journal:  Eur Radiol       Date:  2010-10-21       Impact factor: 5.315

Review 5.  Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy.

Authors:  Jason M Lappé; Clara M Pelfrey; W H Wilson Tang
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

Review 6.  Myocarditis.

Authors:  Leslie T Cooper
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

Review 7.  [Immunoadsorption for treatment of dilated cardiomyopathy].

Authors:  S B Felix; M Dörr; L R Herda; D Beug; A Staudt
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

8.  Outcomes of plasma exchange for severe dilated cardiomyopathy in children.

Authors:  Keiichi Koizumi; Minako Hoshiai; Takako Toda; Nobuyuki Katsumata; Hiroaki Kise; Yohei Hasebe; Yousuke Kouno; Shigeaki Kaga; Shoji Suzuki; Kanji Sugita
Journal:  Heart Vessels       Date:  2016-04-27       Impact factor: 2.037

Review 9.  Pathological ventricular remodeling: mechanisms: part 1 of 2.

Authors:  Jana S Burchfield; Min Xie; Joseph A Hill
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

10.  Plasma exchange for removal of antibeta1-adrenergic receptor antibody in a small child with dilated cardiomyopathy.

Authors:  Hisashi Sugiyama; Minako Hoshiai; Kanji Sugita; Ken-ichi Matsuda
Journal:  Pediatr Cardiol       Date:  2008-11-22       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.